Loading...
Tenofovir/FTC/efavirenz (Atripla) has emerged as the most popular of the currently “preferred” antiretroviral regimens for initial HIV therapy, primarily because it is administered as one pill once daily. In the next year or two, other one-pill regimens — such as the four-drug combination of tenofovir/FTC/elvitegravir/cobicistat (the Quad pill) — are also likely to receive FDA approval. Investigators recently compared this regimen with tenofovir/FTC/efavirenz in a phase II, randomized trial involving 71 treatment-naive adults with viral loads ≥5000 copies/mL and CD4 counts ≥50 cells/mm3. The trial was sponsored by the maker of the Quad pill, which also co-manufactures Atripla.
As has been the case with all integrase inhibitor studies, viral-…